Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): Initial Discovery and Subsequent Development

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5 SUPPL., 2009, Pages 13-18

  Ruggiero, Salvatore L ^a  

^a New York Center for Oral and Maxillofacial Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CANCER PATIENT; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HISTORY, 18TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; JAW DISEASES; JURISPRUDENCE; OSTEONECROSIS; OSTEOPOROSIS; PHOSPHORUS; UNITED STATES;

EID: 64249130498     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.10.005     Document Type: Article

References (34)

1. Blomen L. History of Bisphosphonates: Discovery and History of the Non-medicaluses of Bisphosphonates (1995), Elsevier Science Publishers, Amsterdam
2. Fleisch H., Russell R., and Francis M. Diphosphonates inhibit hydroxyapetite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 (1969) 1262
3. Francis M., Russell R., and Fleisch H. Diphosphonate inhibit formation of calcium phosphate crystals in vitro and pathological calcifications in vivo. Science 165 (1969) 1264
4. Berensen J., Lichtenstein A., and Porter L. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 484
5. Hortobagyi G., Theriualt R., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 335 (1996) 1785
6. Reid I., Nicholson G., Weinstein R., et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101 (1996) 341
7. Rosen L., Gordon D., Kaminski M., et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III double-blind comparative trial. Cancer 7 (2001) 377
8. Rosen L., Gordon D., Tchekmedyian S., et al. Zolendronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blinded randomized trial. J Clin Oncol 21 (2003) 3150
9. Saad F., Gleason D., Murray R., et al. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carconoma. J Natl Cancer Inst 94 (2002) 1458
10. Berenson J., Hillner B., Kyle R., et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719
11. Hillner B., Ingle J., and Berenson J. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 (2000) 1378
12. Hoff A. Osteonecrosis of the jaw in patients receiving bisphosphonate therapy. J Bone Miner Res 20 (2005)
13. Ruggiero S., Gralow J., Marx R., et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Prac 2 (2006) 7
14. FDA. Bisphosphonates and Oral Osteonecrosis (2007), FDA, Washington, DC
15. Edwards B., Gounder M., McKoy J., et al. Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilence and reporting of this serious adverse event. Lancet Oncol (2009) (in press)
16. Felton J. Classic syndromes in occupational medicine. Phosphorus necrosis: A classical occupational disease. Am J Indust Med 3 (1982) 77
17. Hellstein J., and Marek C. Bis-phossy jaw, phossy jaw and the 21st century: Bisphosphonate-associated complication of the jaws. J Oral Maxillofac Surg 62 (2004) 1563
18. Marx R., and Stern D. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment (Vol 1) (2000), Quintessence Publishing Co, Chicago, IL
19. Mehrotra B., Fantasia J., Nissel-Horowitz S., et al. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy. A case report. (abstract 3194). Proc Am Soc Clin Oncol 22 (2003) 795
20. Marx R. Pamidronate (Aredia) and zolendronate (Zometa) induced vascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
21. Rosenberg T., and Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 61 suppl 1 (2003)
22. Ruggiero S., Mehrotra B., and Rosenberg T. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004)
23. Durie B., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates (letter). N Engl J Med 353 (2005) 99
24. Bone H., Hosking D., Devogelaer J., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189
25. Mavrokokki T., Cheng A., Stein B., et al. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 3 (2007) 415
26. Bamias A., Efstathios K., Bamia C., et al. Osteonecrosis of the jaw in cancer patients after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
27. Dimopoulos M., Kastritis E., and Moulopoulos L. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate (abstract). Blood 106 (2005) 637
28. Cafro A., Barbarano L., and Andriani A. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: An Italian experience (abstract). Blood 106 (2005) 5152
29. Tossi P., Zamagni E., and Cangini D. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid (abstract). Blood 106 (2005) 3461
30. Pozzi S., Marcheselli R., and Sacchi S. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw (abstract). Blood 106 (2005) 5057
31. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
32. Dimopoulos M., Kastritis E., Bamia C., et al. Decreased incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid after application of preventive measures. Blood 110 (2007) 1056A
33. Badros A., Evangelos T., Goloubeva O., et al. Long-term follow-up of multiple myeloma patients with osteonecrosis of the jaw. Blood 110 (2007) 1030A
34. Mehrotra B., Fantasia J., and Ruggiero S. Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management guidelines. A large single institutional update. J Clin Oncol 26 (2008) 322